20,239 Shares in DexCom, Inc. (NASDAQ:DXCM) Bought by MFG Wealth Management Inc.

MFG Wealth Management Inc. acquired a new position in DexCom, Inc. (NASDAQ:DXCM) in the fourth quarter, Holdings Channel reports. The institutional investor acquired 20,239 shares of the medical device company’s stock, valued at approximately $1,574,000.

Several other hedge funds have also recently made changes to their positions in the business. Versant Capital Management Inc bought a new stake in shares of DexCom in the 4th quarter valued at approximately $25,000. Riverview Trust Co increased its position in DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after acquiring an additional 232 shares during the last quarter. Heck Capital Advisors LLC purchased a new stake in shares of DexCom in the fourth quarter valued at $38,000. RPg Family Wealth Advisory LLC purchased a new position in shares of DexCom during the 3rd quarter worth about $57,000. Finally, Covestor Ltd grew its holdings in DexCom by 53.7% during the 3rd quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock valued at $64,000 after purchasing an additional 335 shares during the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at DexCom

In related news, EVP Jereme M. Sylvain sold 2,090 shares of the business’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the transaction, the executive vice president now directly owns 83,526 shares in the company, valued at $7,259,244.66. The trade was a 2.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Kevin R. Sayer sold 33,359 shares of the firm’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the sale, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. This represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 42,342 shares of company stock worth $3,628,069. Insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on DXCM shares. Redburn Atlantic upgraded DexCom from a “neutral” rating to a “buy” rating and increased their price target for the stock from $85.00 to $115.00 in a report on Monday, February 3rd. JPMorgan Chase & Co. boosted their price objective on shares of DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Oppenheimer lowered their price target on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Citigroup lifted their target price on DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Finally, Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $98.41.

DexCom Trading Down 2.9 %

Shares of DexCom stock opened at $83.87 on Thursday. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The stock has a market cap of $32.76 billion, a PE ratio of 50.22, a price-to-earnings-growth ratio of 2.26 and a beta of 1.14. The firm has a fifty day moving average price of $82.05 and a 200 day moving average price of $75.13.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.